Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
27.91
-1.48 (-5.04%)
At close: Apr 28, 2026, 4:00 PM EDT
27.92
+0.01 (0.04%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Hims & Hers Health Revenue
In the year 2025, Hims & Hers Health had annual revenue of $2.35B with 59.00% growth. Hims & Hers Health had revenue of $617.82M in the quarter ending December 31, 2025, with 28.41% growth.
Revenue (ttm)
$2.35B
Revenue Growth
+59.00%
P/S Ratio
2.71
Revenue / Employee
$961,358
Employees
2,442
Market Cap
6.36B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elanco Animal Health | 4.72B |
| Dr. Reddy's Laboratories | 3.85B |
| Amneal Pharmaceuticals | 3.02B |
| Neurocrine Biosciences | 2.86B |
| Lantheus Holdings | 1.54B |
| Alkermes | 1.48B |
| Prestige Consumer Healthcare | 1.10B |
| Supernus Pharmaceuticals | 718.95M |
HIMS News
- 18 hours ago - Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors - Business Wire
- 6 days ago - Hims & Hers expands into menopause care as estrogen patch demand rises - Reuters
- 11 days ago - What's Going On With Hims & Hers Shares - Benzinga
- 12 days ago - RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves - CNBC
- 12 days ago - Hims rises as FDA considers broader peptides access; analysts see long-term win - Reuters
- 12 days ago - Hims & Hers surges 4% as peptide policy shift unlocks growth - Invezz
- 12 days ago - Hims & Hers Health Stock Rallies on Regulatory Pivot. It's Not About GLP-1s This Time. - Barrons
- 13 days ago - Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides - Market Watch